NIH PAR · NIAAA · R61, R33
PAR-25-158: Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will…
- NOFO number
- PAR-25-158
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- Clinical trials
- Optional
- Posted
- Nov 25, 2024
- Opens
- Jan 19, 2025
- Expires
- Nov 18, 2026
PAR-25-158 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 19, 2025 | March 18, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 17, 2025 | July 17, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 17, 2025 | November 18, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 18, 2026 | March 17, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 17, 2026 | July 17, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 19, 2026 | November 17, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-158
NIH RePORTER lists 3 projects funded under PAR-25-158 in FY2022–FY2026, with $1.1M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$1.1M
Award dollars under PAR-25-158, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $1.1M |
Institutions with the most funding
- Henry Ford Health + Michigan State University Health Sciences$510K · 1 project
- Yale University$295K · 1 project
- University of Florida$283K · 1 project
Funding institutes
- NIAAA$1.1M · 3
Activity codes funded
- R613 records
Most recent new awards
- Development and Testing of an Ecological Momentary Intervention to Reduce Alcohol Misuse among Young Women of Reproductive Age (opens NIH RePORTER)
Yale University · 1R61AA033188-01 · NIAAA · Notice Sep 10, 2026
$295KR61
- Re-imagining e-SBIRT to reduce stigma and strengthen FASD prevention (opens NIH RePORTER)
Henry Ford Health + Michigan State University Health Sciences · 1R61AA033479-01 · NIAAA · Notice Aug 13, 2026
$510KR61
- Intervention to Improve Sensory Processing in Children with FASD (opens NIH RePORTER)
University of Florida · 1R61AA032062-01A1 · NIAAA · Notice May 14, 2026
$283KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-158. Contact the program officer at the institute that fits your research before applying.
- NIAAA · National Institute on Alcohol Abuse and Alcoholism
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 4 NOSIs to PAR-25-158; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- For the R61 phase, the combined budget for direct costs during the two-year project period may not exceed 350,000 with no more than 225,000 requested in a single year. For the R33 phase, the direct costs must not exceed 500,000 per year.
- Project period
- The project period is limited to 2 years for the R61 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-068.
- Companion NOFOs: PAR-25-159.
Other open NOFOs for R61, R33
- PAR-27-045HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)NCCIH · next due Oct 30, 2026
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
- RFA-NS-25-023HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)NINDS · next due Jan 15, 2027
- RFA-DA-27-016HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)NIDA · next due Feb 10, 2027
- RFA-DC-27-004BRAIN Initiative: Exploratory Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R61 Clinical Trial Not Allowed)NIDCD · next due Feb 11, 2027
- PAR-25-269NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.